TRIMEDX Announces Collaboration With Indiana University Health’s Medical Device Security Lab

TRIMEDX, an industry-leading, technology-enabled provider of clinical engineering, medical device cybersecurity, and clinical asset management solutions, announced a collaboration with Indiana University Health to develop a cybersecurity lab to test medical device security and reduce device security threats as part of the product development process.

The existence of cutting-edge TRIMEDX technology combined with the Medical Device Security Lab at IU Health brings new opportunities for healthcare professionals and the cybersecurity industry. Such innovative technology is not readily available to most health systems, and TRIMEDX hopes to extend the research to others over time.

“The increase in threats and vulnerabilities is exactly why this collaboration is so important,” says Nick Sturgeon, executive director of information security at Indiana University Health. “The collaboration will allow us to be at the forefront of innovation and to continue to protect the health and security of patients.”

Industry-wide, healthcare cybersecurity breaches hit an all-time high in 2021, making the importance of cybersecurity around medical devices even more crucial. In addition, 68% of medical devices are projected to be connected devices by 2025. The security of connected medical devices has never been more critical. This Medical Device Security Lab allows the testing of the healthcare system’s medical devices for vulnerabilities and interoperability.

“Mitigating cybersecurity threats is vital to protecting patient safety and data,” says Sturgeon. “The cutting-edge device testing lab enhances the ability to remediate vulnerabilities before equipment reaches the patient floor.”

The lab will perform enterprise security testing on medical equipment in an environment that poses no risk to patients. It also will enhance TRIMEDX’s unmatched approach toward medical device cybersecurity and innovation in the industry with three headlining objectives:

  • Testing of net-new devices in advance of them being implemented in the hospital.

  • Testing of configurations and security setups to discover what services need to be turned on and what ports need to be available on the network.

  • Active scanning of equipment specific to security testing with no live network or risk of patient impact.

“We expect that this Medical Device Security Lab will pave the way in creating a space for devices to be tested before usage and begin to flag common security issues prior to the implementation of the devices in a healthcare setting,” says Doug Folsom, TRIMEDX chief technology officer and president of cybersecurity. “The intent is to see an overall decrease in device security threats and eventually make this research open and available to many more organizations.”

SourceTRIMEDX

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”